20.59
0.49%
0.10
시간 외 거래:
20.59
전일 마감가:
$20.49
열려 있는:
$20.33
하루 거래량:
530.46K
Relative Volume:
1.52
시가총액:
$1.49B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-187.18
EPS:
-0.11
순현금흐름:
$11.10M
1주 성능:
+1.93%
1개월 성능:
-2.92%
6개월 성능:
+14.52%
1년 성능:
+15.41%
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
20.59 | 1.49B | 384.10M | -9.07M | 11.10M | -0.14 |
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-09-13 | 개시 | Jefferies | Buy |
2024-05-03 | 개시 | Wells Fargo | Overweight |
2020-06-29 | 재확인 | BofA Securities | Buy |
2020-04-01 | 개시 | BofA/Merrill | Buy |
2019-03-11 | 개시 | Barclays | Overweight |
2018-12-12 | 재확인 | Wedbush | Outperform |
2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $470k - Investing.com
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Fmr LLC - Defense World
Kiniksa Pharmaceuticals CFO sells shares worth $593,997 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals CFO sells shares worth $593,997 - Investing.com
Kiniksa Pharmaceuticals CFO sells shares worth $323,008 By Investing.com - Investing.com Canada
Kiniksa Pharmaceuticals CFO sells shares worth $323,008 - Investing.com India
KNSA (Kiniksa Pharmaceuticals International) Treasury Stock : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
Kiniksa Pharmaceuticals officer sells $194k in stock By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals officer sells $194k in stock - Investing.com India
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - Marketscreener.com
Principal Financial Group Inc. Sells 14,100 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals COO sells shares valued at $357,680 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals COO sells shares valued at $357,680 - Investing.com India
HHLR Advisors, Ltd. Reduces Stake in Kiniksa Pharmaceuticals Int - GuruFocus.com
Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025? - Insider Monkey
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | KNSA Stock News - StockTitan
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference - GlobeNewswire
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Kiniksa Pharmaceuticals International PLC (KNSA) Trading Down 3. - GuruFocus.com
Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise LossHere Are Analysts Latest Forecasts - Yahoo Finance
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earning - GuruFocus.com
Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Kiniksa Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ... - Yahoo Finance
Kiniksa Pharm's Revenue Surges 67% in Q3 - The Motley Fool
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Gap Down to $24.04 on Oct 29 - GuruFocus.com
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiniksa Pharmaceuticals Q3 2024 Earnings: EPS Miss, Revenue Beats Estimates with $112.2 Million - GuruFocus.com
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution - GlobeNewswire
Exploring Kiniksa Pharmaceuticals's Earnings Expectations - Benzinga
What To Expect From Kiniksa Pharmaceuticals International PLC (K - GuruFocus.com
What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings - Yahoo Finance
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning - GlobeNewswire
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis - StockTitan
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 - GlobeNewswire
Kiniksa Pharmaceuticals COO Eben sells shares worth $456,790 - Investing.com India
Kiniksa Pharmaceuticals COO Eben sells shares worth $456,790 By Investing.com - Investing.com UK
High Growth Tech Stocks To Watch In October 2024 - Simply Wall St
What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing' - Yahoo Finance
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kiniksa Pharmaceuticals International Plc 주식 (KNSA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Tessari Eben | CHIEF OPERATING OFFICER |
Dec 16 '24 |
Sale |
20.44 |
23,017 |
470,467 |
95,975 |
자본화:
|
볼륨(24시간):